<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2018-4-46-52</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-697</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭНДОВАСКУЛЯРНЫЕ ВМЕШАТЕЛЬСТВА НА КОРОНАРНЫХ АРТЕРИЯХ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ENDOVASCULAR CORONARY INTERVENTIONS</subject></subj-group></article-categories><title-group><article-title>Предикторы отдаленных неблагоприятных событий после плановых эндоваскулярных вмешательств на коронарных артериях</article-title><trans-title-group xml:lang="en"><trans-title>Predictors of long term adverse events after scheduled endovascular coronary interventions</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2665-9108</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вершинина</surname><given-names>Е. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Vershinina</surname><given-names>E. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вершинина Елена Олеговна — кандидат медицинских наук, н. с. отделения реабилитации больных сердечно-сосудистыми заболеваниями</p><p>Тел.: +7 (382) 256-58-31</p></bio><email xlink:type="simple">oliver@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7123-0645</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Репин</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Repin</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Репин Алексей Николаевич — доктор медицинских наук, профессор, руководитель отделения реабилитации больных сердечно-сосудистыми заболеваниями</p></bio><email xlink:type="simple">ran@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт кардиологии ФГБНУ “Томский национальный исследовательский медицинский центр Российской академии наук”</institution></aff><aff xml:lang="en"><institution>SRI of Cardiology “Tomsk National Research Medical Center of RAS”</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>20</day><month>08</month><year>2018</year></pub-date><volume>17</volume><issue>4</issue><fpage>46</fpage><lpage>52</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Вершинина Е.О., Репин А.Н., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Вершинина Е.О., Репин А.Н.</copyright-holder><copyright-holder xml:lang="en">Vershinina E.O., Repin A.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/697">https://cardiovascular.elpub.ru/jour/article/view/697</self-uri><abstract><sec><title>Цель</title><p>Цель. Определить частоту и  выявить предикторы отдаленных неблагоприятных сердечно-сосудистых событий после плановых чрескожных коронарных вмешательств (ЧКВ).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Частота комбинированной конечной точки исследования, включающей смерть от сердечно-сосудистых причин, острый коронарный синдром и острое нарушение мозгового кровообращения (МАССЕ  — Major Adverse Cardiac and Cerebrovascular Events) была оценена у 151 пациента через 6 лет после выборочного ЧКВ путем анализа медицинской документации и телефонного интервью.</p></sec><sec><title>Результаты</title><p>Результаты. Через 6 лет после плановых ЧКВ смерть от сердечнососудистых причин была зарегистрирована у  10,6% пациентов, острый коронарный синдром развился у 34,4%, острое нарушение мозгового кровообращения — у 6,6%. В целом MAСCE отмечены у  40,4% пациентов. Предикторами MACCE в  отдаленный период были хроническая болезнь почек, контраст-индуцированное острое повреждение почек, исходный уровень С-реактивного белка &gt;5,5 мг/л. Рестенозы ранее установленных стентов увеличивали риск развития MACCE в 8,09 раза, хроническая обструктивная болезнь легких — в 3,4 раза, фибрилляция предсердий — в 2,84 раза, отягощенная наследственность по  сердечно-сосудистым заболеваниям — в 2,94 раза, очень высокий риск развития контраст-индуцированной нефропатии (≥11 баллов по шкале R. Mehran) — в 2,15 раза.</p></sec><sec><title>Заключение</title><p>Заключение. Определение предикторов отдаленных неблагоприятных сердечно-сосудистых событий у пациентов после плановых ЧКВ позволяет на основе использования простых клинических характеристик выделять группы больных с высоким остаточным риском, которые требуют своевременного применения более активных стратегий вторичной профилактики при последующем наблюдении.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To evaluate the rate and reveal the predictors of long term adverse cardiovascular events after scheduled percutaneous coronary interventions (PCI).</p></sec><sec><title>Material and methods</title><p>Material and methods. The rate of combination endpoint (МАССЕ — Major Adverse Cardiac and Cerebrovascular Events) was assessed in 151 patient in 6 years after selective PCI by medical data analysis and phone based interview.</p></sec><sec><title>Results</title><p>Results. In 6 years after scheduled PCI the mortality from cardiovascular events was in 10,6% patients, acute coronary syndrome developed in 34,4%, stroke in 6,6%. In general MACCE were noted in 40,4%. The predictors of MACCE in long term period were chronic kidney disease, contrast-induced kidney damage, baseline C-reactive protein &gt;5,5 mg/mL. Restenoses of the previously placed stents increased the risk of MACCE 8,09 times, chronic obstructive pulmonary disease — 3,4 times, atrial fibrillation — 2,84 times, heredity by cardiovascular diseases — 2,94 times, and the very high risk of contrast-induced nephropathy (≥11 points by Mehran) — 2,15 times.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ишемическая болезнь сердца</kwd><kwd>стабильная стенокардия</kwd><kwd>чрескожные коронарные вмешательства</kwd><kwd>отдаленные результаты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>coronary heart disease</kwd><kwd>stable angina</kwd><kwd>percutaneous interventions</kwd><kwd>long term results</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267-315. doi:10.1093/eurheartj/ehv320. Epub 2015 Aug 29.</mixed-citation><mixed-citation xml:lang="en">Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267-315. doi:10.1093/eurheartj/ehv320. Epub 2015 Aug 29.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Grayson AD, Moore RK, Jackson M, et al. North West Quality Improvement Programme in Cardiac Interventions. Multivariate prediction of major adverse cardiac events after 9914 percutaneous coronary interventions in the north west of England. Heart. 2006;92:658-63. doi:10.1136/hrt.2005.066415</mixed-citation><mixed-citation xml:lang="en">Grayson AD, Moore RK, Jackson M, et al. North West Quality Improvement Programme in Cardiac Interventions. Multivariate prediction of major adverse cardiac events after 9914 percutaneous coronary interventions in the north west of England. Heart. 2006;92:658-63. doi:10.1136/hrt.2005.066415</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrastinduced nephropathy after percutaneous coronary intervention: development and initial validation. JACC. 2004; 44:1393-9. doi:10.1016/j.jacc.2004.06.068.</mixed-citation><mixed-citation xml:lang="en">Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrastinduced nephropathy after percutaneous coronary intervention: development and initial validation. JACC. 2004; 44:1393-9. doi:10.1016/j.jacc.2004.06.068.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Вершинина Е. О., Репин А. Н., Сальникова Е. С. Нагрузочные дозы статинов при плановых эндоваскулярных вмешательствах на коронарных артериях. Сердце: журнал для практикующих врачей. 2016;15(3):181-91. doi:10.18087/rhj.2016.3.2181.</mixed-citation><mixed-citation xml:lang="en">Vershinina EO, Repin AN, Salnikova ES. Loading dose statin therapy in elective endovascular interventions on the coronary arteries. Serdce: zhurnal dlya praktikuyushchih vrachej. 2016;15(3):181-91. (In Russ.) doi:10.18087/rhj.2016.3.2181.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Rapsomaniki E, Shah A, Perel P, et al. Prognostic models for stable coronary artery disease based on electronic health record cohort of 102 023 patients. Eur Heart J. 2014;35:844-52. doi:10.1093/eurheartj/eht533. Epub 2013 Dec 17.</mixed-citation><mixed-citation xml:lang="en">Rapsomaniki E, Shah A, Perel P, et al. Prognostic models for stable coronary artery disease based on electronic health record cohort of 102 023 patients. Eur Heart J. 2014;35:844-52. doi:10.1093/eurheartj/eht533. Epub 2013 Dec 17.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Вершинина Е. О., Репин А. Н., Рябова Т. Р. Влияние мультифокального атеросклероза на ближайшие и отдаленные результаты планового эндоваскулярного лечения ишемической болезни сердца. Сибирский медицинский журнал (г. Томск). 2014;29(3):87-93.</mixed-citation><mixed-citation xml:lang="en">Vershininа EO, Repin AN, Ryabova TR. The impact of multifocal atherosclerosis on the early and late outcomes of elective endovascular treatment of ischemic heart disease. The Siberian Medical Journal (Tomsk). 2014;29(3):87-93. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Amarenco P, Lavallee PC, Labreuche J, et al. Coronary artery disease and risk of major vascular events after cerebral infarction. Stroke. 2013;44:1505-11. doi:10.1161/ STROKEAHA.111.000142.</mixed-citation><mixed-citation xml:lang="en">Amarenco P, Lavallee PC, Labreuche J, et al. Coronary artery disease and risk of major vascular events after cerebral infarction. Stroke. 2013;44:1505-11. doi:10.1161/ STROKEAHA.111.000142.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wauters E, Carruthers KF, Buysschaert I, et al. Influence of 23 coronary artery disease variants on recurrent myocardial infarction or cardiac death: The GRACE Genetics Study. Eur Heart J. 2013;34:993-1001. doi:10.1093/eurheartj/ehs389. Epub 2012 Nov 15.</mixed-citation><mixed-citation xml:lang="en">Wauters E, Carruthers KF, Buysschaert I, et al. Influence of 23 coronary artery disease variants on recurrent myocardial infarction or cardiac death: The GRACE Genetics Study. Eur Heart J. 2013;34:993-1001. doi:10.1093/eurheartj/ehs389. Epub 2012 Nov 15.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Nakatani D, Sakata Y, Suna S, et al. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. Circ J. 2013;77:439-46. doi:10.1253/circj.CJ-11-1059.</mixed-citation><mixed-citation xml:lang="en">Nakatani D, Sakata Y, Suna S, et al. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. Circ J. 2013;77:439-46. doi:10.1253/circj.CJ-11-1059.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Raber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation. 2011;123:2819-28. doi:10.1161/ CIRCULATIONAHA.110.004762. Epub 2011 Jun 6.</mixed-citation><mixed-citation xml:lang="en">Raber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation. 2011;123:2819-28. doi:10.1161/ CIRCULATIONAHA.110.004762. Epub 2011 Jun 6.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Otsuka F, Byrne RA, Yahagi K, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J. 2015;36:2147-59. doi:10.1093/eurheartj/ehv205. Epub 2015 May 20.</mixed-citation><mixed-citation xml:lang="en">Otsuka F, Byrne RA, Yahagi K, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J. 2015;36:2147-59. doi:10.1093/eurheartj/ehv205. Epub 2015 May 20.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Palhais N, Arroyo D, Lehmann S, et al. Ten-year clinical follow-up after sirolimus-eluting stent implantation. Am Heart J. 2014;167:893-9. doi:10.1016/j.ahj.2013.12.013.</mixed-citation><mixed-citation xml:lang="en">Palhais N, Arroyo D, Lehmann S, et al. Ten-year clinical follow-up after sirolimus-eluting stent implantation. Am Heart J. 2014;167:893-9. doi:10.1016/j.ahj.2013.12.013.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Yamaji K, Raber L, Zanchin T, et al. Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial. Eur Heart J. 2016;37:3386-95. doi:10.1093/eurheartj/ehw343. Epub 2016 Aug 30.</mixed-citation><mixed-citation xml:lang="en">Yamaji K, Raber L, Zanchin T, et al. Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial. Eur Heart J. 2016;37:3386-95. doi:10.1093/eurheartj/ehw343. Epub 2016 Aug 30.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hu WS, Lee JH, Tsai MK, et al. А novel cardiovascular death prediction model for Chinese individuals: A prospective cohort study of 381,963 study participants. Atherosclerosis. 2017;264:19-28. doi:10.1016/j.atherosclerosis.2017.07.016. Epub 2017 Jul 14.</mixed-citation><mixed-citation xml:lang="en">Hu WS, Lee JH, Tsai MK, et al. А novel cardiovascular death prediction model for Chinese individuals: A prospective cohort study of 381,963 study participants. Atherosclerosis. 2017;264:19-28. doi:10.1016/j.atherosclerosis.2017.07.016. Epub 2017 Jul 14.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Вершинина Е. О., Репин А. Н. Острое перипроцедурное повреждение почек при плановых чрескожных коронарных вмешательствах. Евразийский кардиологический журнал. 2017;3:114.</mixed-citation><mixed-citation xml:lang="en">Vershininа EO, Repin AN. Acute periprocedural kidney injury in elective percutaneous coronary interventions. Eurasian Heart J. 2017;3:114. (In Russ.)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
